The mechanism by which empagliflozin- An SGLT2 inhibitor provides cardiovascular (CV) protection particularly in heart failure is not completely understood considering the absence of SGLT2 expression in cardiac tissue [[12], [13]]. This evidence concerns the gene SLC5A2 and heart failure.